J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):e159-e170. doi: 10.1016/j.japh.2020.11.008. Epub 2020 Dec 9.
The introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infections has revolutionized outcomes for patients with HCV. Cost-effective use of these antivirals in addition to ensuring patient adherence is of paramount importance.
The goal of this article is to describe the processes by which a tertiary care, multisite institution managed the complexities involved in administering DAA treatment and managing the increased cost of therapy. Specifically, the objectives of this article are to describe the development of a multidisciplinary HCV management program and the role of pharmacists in this program, including formulary management strategies and monitoring of DAAs use in our institution, development of guidelines, electronic prescribing protocols and order sets, and specific outcomes based on a concurrent medication use evaluation.
King Faisal Specialist Hospital and Research Centre is a tertiary care referral hospital. As a tertiary referral hospital, it offers primary and highly specialized inpatient and outpatient medical care. The process of selecting and developing institutional HCV management program is described.
This article provides key details regarding how a multidisciplinary HCV program using DAAs can be implemented successfully at a tertiary care facility. Key facets of our innovation include establishing formulary guidelines, setting up eligibility criteria for patients, and establishing an HCV taskforce and multidisciplinary HCV program clinic.
Medication use evaluations were regularly conducted to monitor sustained virologic response rates, adherence to guidelines, adverse reactions, and drug interactions.
Formulary guidelines, setting up an eligibility criterion for patients, and an HCV taskforce and multidisciplinary HCV program clinic were established.
The involvement of pharmacists in a multidisciplinary HCV program in outpatient settings resulted in improved formulary decision making, reduction of costs, and improvement of adherence to institutional guidelines.
The role of a pharmacist in the management of patients with HCV with DAAs is important. Pharmacists play an integral part in medication management and overall reduction in health care expenditure. Many disease management programs can be complemented with pharmacists to improve patient care and reduce cost.
HCV treatment is challenging, and a multidisciplinary approach to treat HCV is critical. It is a rapidly evolving field; therefore, it requires dynamic formulary management and collaborative practice approaches to monitor pharmacotherapy carefully and efficiently. Clinical pharmacists play a pivotal role within the multidisciplinary team by providing support to both patients and health care providers with regard to the treatment of HCV.
直接作用抗病毒药物（DAAs）的引入改变了丙型肝炎病毒（HCV）感染者的治疗结果。在确保患者依从性的前提下，以具有成本效益的方式使用这些抗病毒药物至关重要。
本文旨在描述一家三级保健多院区机构管理丙型肝炎病毒治疗的复杂性和治疗费用增加的相关过程。具体而言，本文的目标是描述多学科丙型肝炎病毒管理项目的发展，以及药剂师在该项目中的作用，包括我们机构的用药清单管理策略和 DAA 药物使用监测、指南的制定、电子处方协议和医嘱集，以及基于同期药物使用评估的具体结果。
法伊萨尔国王专科医院和研究中心是一家三级保健转诊医院。作为一家三级转诊医院，它提供初级和高度专业化的住院和门诊医疗服务。本文描述了选择和开发机构丙型肝炎病毒管理项目的过程。
本文提供了关于如何在三级保健机构成功实施使用 DAA 的多学科丙型肝炎病毒项目的关键细节。我们的创新的关键方面包括制定用药清单指南、为患者设定资格标准，以及建立丙型肝炎病毒工作组和多学科丙型肝炎病毒项目诊所。
定期进行药物使用评估，以监测持续病毒学应答率、对指南的依从性、不良反应和药物相互作用。
制定用药清单指南、为患者设定资格标准以及建立丙型肝炎病毒工作组和多学科丙型肝炎病毒项目诊所。
药剂师参与丙型肝炎病毒多学科门诊项目，使用药清单决策更加合理、降低成本，并提高了对机构指南的依从性。
药剂师在丙型肝炎病毒患者 DAA 治疗管理中的作用很重要。药剂师在药物管理和整体降低医疗保健支出方面发挥着不可或缺的作用。许多疾病管理项目都可以通过药剂师来补充，以改善患者护理和降低成本。
丙型肝炎病毒治疗具有挑战性，采用多学科方法治疗丙型肝炎病毒至关重要。这是一个快速发展的领域，因此需要动态的用药清单管理和协作实践方法来仔细、有效地监测药物治疗。临床药剂师在多学科团队中发挥关键作用，为丙型肝炎病毒治疗的患者和医疗保健提供者提供支持。
